De Novo Guidance Doesn’t Cut Review Time Enough, Industry Says

Industry is skeptical of FDA claims that the plan mapped out in a recent draft guidance on de novo petitions will speed the review process for devices that aren’t a good fit for either the 510(k) or PMA programs.